Supreme Court: 180-Day Biosimilar Exclusivity Can Start Any Time, Not Just After Approval

In a decision that reshapes the patent dance between biosimilar applicants and reference holders — and could affect the course of billions of dollars in the pharmaceutical industry — the U.S. Supreme Court ruled biosimilar manufacturers do not have to wait for FDA approval before beginning a six-month delay on commercial marketing.
Source: Drug Industry Daily